Transgene Receives Approval from the French Health Authority (ANSM) to Initiate Two Clinical Trials of its Lead myvac(TM) Individualized Immunotherapy TG4050

information fournie par Boursorama •16/09/2019 à 17:45

Transgene Receives Approval from the French Health Authority (ANSM) to Initiate Two Clinical Trials of its Lead myvac(TM) Individualized Immunotherapy TG4050


- International Phase 1 clinical trials expected to start in 2019
- In France, the studies will be conducted at Institut Curie and Toulouse-Oncopole
- Clinical trials co-funded by Transgene and its collaboration partner NEC

Strasbourg, France, September 16, 2019, 5:45 p.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of solid tumors, today announces it has received approval from the French National Agency for the Safety of Medicines and Health Products (ANSM) to proceed with two Phase 1 clinical trials of its lead myvac(TM) candidate TG4050. TG4050 is a novel individualized immunotherapeutic designed to elicit an immune response directed specifically against the patient's own tumor.

Two international clinical studies due to start in 2019

.../...